ARTICLE | Clinical News

Torezolid phosphate: SPA received

August 15, 2011 7:00 AM UTC

Trius received an SPA from FDA for a double-blind Phase III trial evaluating once-daily 200 mg IV and oral torezolid for 6 days vs. twice-daily 600 mg Zyvox linezolid for 10 days in 658 patients. Patients will receive the IV torezolid for >=1 day and then oral torezolid at the investigator's discretion. Trius plans to begin the trial next quarter. ...